A systematic review of the effectiveness of adalimumab

More documents

Recommendations

Info

208 Appendix 10 TABLE 137 Variation 11: TNF inhibitors last (20,000 patients) Option Cost (£) QSE QALYs QSE Adal 26,797 159 1.5818 0.0202 Etan 38,999 222 2.4968 0.0240 Adal+MTX 26,804 163 1.7647 0.0206 Etan+MTX 38,450 220 2.4194 0.0240 Infl+MTX 26,971 155 1.5903 0.0205 Base 2,850 11 1.0352 0.0185 Comparison Diff. cost (£) QSE Diff. QALY QSE Adal – Base 23,946 158 0.5466 0.0135 Etan – Base 36,149 220 1.4617 0.0190 Ad+M – Base 23,954 161 0.7295 0.0144 Et+M – Base 35,599 218 1.3842 0.0193 In+M – Base 24,121 154 0.5551 0.0138 Ad+M – Adal 7 222 0.1829 0.0163 Etan – Et+M 550 300 0.0775 0.0243 Etan – Adal 12,202 265 0.9151 0.0205 Et+M – Ad+M 11,645 265 0.6547 0.0213 In+M – Ad+M 167 220 –0.1744 0.0166 Et+M – In+M 11,479 261 0.8291 0.0209 Comparison ICER (£ per QALY) Quasi-CI Adal – Base 43,800 41,700 to 46,200 Etan – Base 24,700 24,000 to 25,500 Ad+M – Base 32,800 31,500 to 34,300 Et+M – Base 25,700 25,000 to 26,500 In+M – Base 43,500 41,300 to 45,800 Ad+M – Adal Adal+MTX more effective than Adal alone; diff. cost not significant Et+M – Etan Etan alone more effective than Etan+MTX; diff. cost not significant Etan – Adal 13,300 12,600 to 14,200 Et+M – Ad+M 17,800 16,500 to 19,300 In+M – Ad+M Adal+MTX more effective than Infl+MTX; diff. cost not significant Et+M – In+M 13,800 13,000 to 14,900 Variation 12 In this variation, survival times on TNF inhibitors were increased by 50% compared to <strong>the</strong> base case. TABLE 138 Variation 12: TNF inhibitors first (100,000 patients) Option Cost (£) QSE QALYs QSE Adal 56,493 116 9.0677 0.0172 Etan 70,886 132 9.4132 0.0179 Adal+MTX 56,728 117 8.7667 0.0164 Etan+MTX 71,163 133 9.1543 0.0174 Infl+MTX 55,594 111 8.5600 0.0164 Base 15,320 21 8.3179 0.0158 Comparison Diff. cost (£) QSE Diff. QALY QSE Adal – Base 41,173 113 0.7498 0.0172 Etan – Base 55,566 129 1.0953 0.0177 Ad+M – Base 41,408 115 0.4488 0.0168 Et+M – Base 55,843 129 0.8364 0.0175 In+M – Base 40,275 109 0.2421 0.0168 Ad+M – Adal 235 156 –0.3010 0.0174 Et+M – Etan 277 173 –0.2589 0.0184 continued
TABLE 138 Variation 12: TNF inhibitors first (100,000 patients) (cont’d) © Queen’s Printer and Controller <strong>of</strong> HMSO 2006. All rights reserved. Health Technology Assessment 2006; Vol. 10: No. 42 Etan – Adal 14,393 164 0.3455 0.0180 Et+M – Ad+M 14,435 166 0.3876 0.0177 Ad+M – In+M 1,133 154 0.2067 0.0171 Et+M – In+M 15,569 163 0.5942 0.0177 Comparison ICER (£ per QALY) Quasi-CI Adal – Base 54,900 52,500 to 57,600 Etan – Base 50,700 49,100 to 52,400 Ad+M – Base 92,300 85,800 to 99,800 Et+M – Base 66,800 64,100 to 69,700 In+M – Base 166,000 146,000 to 193,000 Ad+M – Adal Adal alone more effective than Adal+MTX; diff. cost not significant Et+M – Etan Etan alone more effective than Etan+MTX; diff. cost not significant Etan – Adal 41,700 37,600 to 46,600 Et+M – Ad+M 37,200 34,000 to 41,100 Ad+M – In+M 5,480 3,740 to 7,220 Et+M – In+M 26,200 24,600 to 28,000 TABLE 139 Variation 12: TNF inhibitors third (early RA values) (100,000 patients) Option Cost (£) QSE QALYs QSE Adal 54,611 111 6.5295 0.0154 Etan 67,263 127 7.0841 0.0165 Adal+MTX 54,797 112 6.7368 0.0154 Etan+MTX 67,427 128 7.2198 0.0165 Infl+MTX 54,229 107 6.6898 0.0154 Base 16,488 23 5.3802 0.0137 Comparison Diff. cost (£) QSE Diff. QALY QSE Adal – Base 38,123 108 1.1492 0.0151 Etan – Base 50,775 123 1.7039 0.0161 Ad+M – Base 38,309 109 1.3566 0.0153 Et+M – Base 50,939 124 1.8396 0.0162 In+M – Base 37,741 104 1.3096 0.0152 Ad+M – Adal 186 147 0.2074 0.0162 Et+M – Etan 164 162 0.1357 0.0176 Etan – Adal 12,652 156 0.5547 0.0169 Et+M – Ad+M 12,630 156 0.4830 0.0169 Ad+M – In+M 568 144 0.0470 0.0162 Et+M – In+M 13,198 153 0.5300 0.0169 Comparison ICER (£ per QALY) Quasi-CI Adal – Base 33,200 32,300 to 34,100 Etan – Base 29,800 29,200 to 30,400 Ad+M – Base 28,200 27,600 to 28,900 Et+M – Base 27,700 27,200 to 28,200 In+M – Base 28,800 28,100 to 29,500 Ad+M – Adal Adal+MTX more effective than Adal alone; diff. cost not significant Et+M – Etan Etan+MTX more effective than Etan alone; diff. cost not significant Etan – Adal 22,800 21,400 to 24,400 Et+M – Ad+M 26,100 24,300 to 28,200 Ad+M – In+M 12,100 6,510 to 83,000 Et+M – In+M 24,900 23,300 to 26,700 209
Page 1 and 2:
A systematic review of the effectiv
Page 3 and 4:
A systematic review of the effectiv
Page 5 and 6:
Objectives: This report reviews the
Page 7:
Glossary and list of abbreviations
Page 10 and 11:
viii Glossary and list of abbreviat
Page 13 and 14:
Background Rheumatoid arthritis (RA
Page 15:
increased risk of serious infection
Page 19 and 20:
Summary RA is a common, chronic, in
Page 21 and 22:
(IL-2) and interleukin-6 (IL-6), pr
Page 23 and 24:
Assessment of response to DMARDs Re
Page 25 and 26:
combination with methotrexate or al
Page 27:
disease between clinic appointments
Page 30 and 31:
14 Effectiveness in juvenile arthri
Page 32 and 33:
16 Effectiveness adalimumab plus me
Page 34 and 35:
18 Effectiveness Monoclonal Antibod
Page 36 and 37:
20 TABLE 1 Description of included
Page 38 and 39:
22 TABLE 2 Quality of included RCTs
Page 40 and 41:
24 Effectiveness change in modified
Page 42 and 43:
26 Effectiveness TABLE 4 Meta-analy
Page 44 and 45:
28 Effectiveness Review: Adalimumab
Page 46 and 47:
30 Effectiveness Review: Adalimumab
Page 48 and 49:
32 TABLE 6 Effectiveness Descriptio
Page 50 and 51:
34 TABLE 6 Effectiveness Descriptio
Page 52 and 53:
36 TABLE 7 Effectiveness Quality of
Page 54 and 55:
38 Effectiveness etanercept trials.
Page 56 and 57:
40 Effectiveness TABLE 9 Summary of
Page 58 and 59:
42 Effectiveness Review: Etanercept
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
54 Effectiveness TABLE 11 Summary o
Page 72 and 73:
56 TABLE 12 Description of included
Page 74 and 75:
58 TABLE 13 Quality of included RCT
Page 76 and 77:
60 Effectiveness per week and escal
Page 78 and 79:
62 Effectiveness significant advant
Page 80 and 81:
64 Effectiveness Review: Infliximab
Page 82 and 83:
66 Effectiveness Review: Infliximab
Page 84 and 85:
68 Effectiveness FIGURE 44 Malignan
Page 86 and 87:
70 TABLE 17 Effectiveness Summary o
Page 89 and 90:
Summary of review of existing econo
Page 91 and 92:
TABLE 20 Summary of published ICERs
Page 93 and 94:
TABLE 21 Published etanercept econo
Page 95 and 96:
TABLE 23 Published economic analyse
Page 97 and 98:
TABLE 25 Treatment sequences: adali
Page 99 and 100:
management of RA, i.e. 1st and 2nd
Page 101 and 102:
To estimate the long-term consequen
Page 103 and 104:
TABLE 32 TNF inhibitors as last act
Page 105 and 106:
TABLE 34 Basic structure of the mod
Page 107 and 108:
een quit on grounds of toxicity, ad
Page 109 and 110:
TABLE 39 Strategy set: adalimumab a
Page 111 and 112:
TABLE 43 Beta distributions for HAQ
Page 113 and 114:
TABLE 44 Early cessation of DMARDs:
Page 115 and 116:
TABLE 46 Unit costs for tests and v
Page 117 and 118:
following properties, according to
Page 119 and 120:
TABLE 52 Base case: TNF inhibitors
Page 121 and 122:
TABLE 54 Base case: TNF inhibitors
Page 123 and 124:
TABLE 59 Third TNF inhibitor follow
Page 125 and 126:
TABLE 65 Sensitivity analyses: TNF
Page 127 and 128:
TABLE 67 Sensitivity analyses: TNF
Page 129:
The substantial economic impact of
Page 133 and 134:
Summary Effectiveness: principal fi
Page 135 and 136:
inhibitors, although the incrementa
Page 137 and 138:
introduce bias which generally exag
Page 139:
Adalimumab, etanercept and inflixim
Page 143 and 144:
1. Jobanputra P, Barton P, Bryan S,
Page 145 and 146:
46. Young A, Dixey J, Cox N, Davies
Page 147 and 148:
tumor necrosis factor therapy in th
Page 149 and 150:
arthritis: a 12-week, double-blind,
Page 151 and 152:
171. Geborek P, Crnkic M, Petersson
Page 153 and 154:
216. Schotte H, Willeke P, Mickholz
Page 155 and 156:
The Health Assessment Questionnaire
Page 157 and 158:
Cochrane Library (CENTRAL) 2005 Iss
Page 159 and 160:
Appendix 3 © Queen’s Printer and
Page 161:
TABLE 69 Studies excluded from clin
Page 164 and 165:
148 Appendix 4 TABLE 71 Meta-analys
Page 166 and 167:
150 Appendix 4 TABLE 73 Meta-analys
Page 168 and 169:
152 Appendix 4 Infliximab versus pl
Page 170 and 171:
154 Appendix 4 Infliximab plus MTX
Page 173: Ovid MEDLINE(R) 1966 to February we
Page 177 and 178: Appendix 8 © Queen’s Printer and
Page 179 and 180: TABLE 79 Wong et al., 2002 161 © Q
Page 181 and 182: TABLE 80 Kobelt et al., 2003 162 (c
Page 183 and 184: TABLE 82 Brennan et al., 2004 160
Page 185 and 186: TABLE 83 Kobelt et al., 2004 163 (c
Page 187 and 188: TABLE 85 Bansback et al., 2005 166
Page 189: TABLE 86 Kobelt et al., 2005 167 (c
Page 192 and 193: 176 Appendix 9 TABLE 89 Strategy se
Page 195 and 196: Extensive sensitivity analysis was
Page 197 and 198: TABLE 96 Variation 1: TNF inhibitor
Page 199 and 200: TABLE 99 Variation 2: TNF inhibitor
Page 201 and 202: TABLE 102 Variation 3: TNF inhibito
Page 221 and 222: TABLE 132 Variation 10: TNF inhibit
Page 223: TABLE 135 Variation 11: TNF inhibit
Page 243: TABLE 165 Variation 18: TNF inhibit
Page 247 and 248: Volume 1, 1997 No. 1 Home parentera
Page 249 and 250: No. 3 Screening for sickle cell dis
Page 251 and 252: No. 25 A rapid and systematic revie
Page 253 and 254: No. 11 First and second trimester a
Page 255 and 256: No. 23 Clinical effectiveness and c
Page 257 and 258: No. 28 Outcomes of electrically sti
Page 259: No. 28 Adefovir dipivoxil and pegyl
Page 262 and 263: 246 Health Technology Assessment Pr
Page 264: 248 Health Technology Assessment Pr
show all

A systematic review of the effectiveness of adalimumab

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?